Biorestorative Therapies, Inc. (NASDAQ:BRTX) Shares Shorted: Short Interest Down 69.2% in September

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large decrease in short interest in September. As of September 15th, there was short interest totaling 11,586 shares, a decrease of 69.2% from the August 31st total of 37,641 shares. Based on an average trading volume of 40,553 shares, the short-interest ratio is currently 0.3 days. Currently, 1.0% of the company’s stock are sold short.

Biorestorative Therapies Stock Performance

BRTX traded up $0.04 on Friday, hitting $2.55. The company had a trading volume of 27,998 shares, compared to its average volume of 34,144. The stock has a market capitalization of $3.52 million, a price-to-earnings ratio of -0.12 and a beta of 0.83. The stock has a fifty day moving average price of $3.97 and a 200-day moving average price of $5.30. Biorestorative Therapies has a 12-month low of $2.44 and a 12-month high of $34.60.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, August 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Biorestorative Therapies Company Profile

BioRestorative Therapies, Inc is a biotechnology company focused on developing regenerative medicine products using cell-based therapies. The company’s research programs are aimed primarily at treating musculoskeletal disorders and conditions associated with metabolic health.

Its principal product candidate is BRTX-100, an autologous cell therapy being developed for painful degenerative disc disease. The treatment is designed to use a patient’s own bone marrow-derived cells, which are processed and expanded before being administered to the affected spinal disc.